The latest announcement is out from Neuren Pharmaceuticals Limited ( (AU:NEU) ).
Neuren Pharmaceuticals Limited has announced an update on its ongoing share buy-back program, reporting the purchase of 16,341 ordinary fully paid securities on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of therapies for neurodevelopmental disorders. The company is listed on the Australian Securities Exchange under the code NEU.
YTD Price Performance: -11.60%
Average Trading Volume: 738
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $1.01B
Learn more about NEU stock on TipRanks’ Stock Analysis page.